It’s estimated that 75% of adults in the US are obese or overweight. Conventional weight reduction strategies have persistently fallen quick of their means to deal with weight problems. As well as, in the US alone, a staggering 96 million people discover themselves prediabetic, and it’s predicted that 1 billion individuals worldwide might grapple with diabetes by the 12 months 2050.
Many individuals embarking on their weight reduction journey have skilled the irritating limitations of typical approaches. These strategies usually revolve round simplistic mantras like “eat much less and transfer extra,” which, whereas theoretically sound, continuously show inadequate for sustainable weight reduction. The issue lies within the oversimplification of the advanced elements that contribute to weight problems. It’s not merely about decreasing caloric consumption and rising bodily exercise; it’s about understanding the intricate interaction of genetics, metabolism, way of life, and private preferences.
At Samsung Subsequent, we acknowledge the ability of wellness as a pathway to improved well being outcomes and imagine in integrating diet as a part of a complete healthcare method. Weight reduction options, significantly for nondiabetics, are most of the time thought-about to be wellness choices. Nevertheless, we imagine diet also needs to be seen as a healthcare resolution to enhance medical outcomes.
Signos, with its early detection strategies and easy way of life changes, gives a metabolic-focused resolution that may help people on their weight reduction journeys. By combining steady glucose monitoring (CGM) know-how with an AI-driven app, Signos delivers real-time glucose monitoring and customized diet options. Members obtain a equipment with a CGM and entry to the app throughout their subscription, which learns particular person glucose reactions to meals, serving to members make knowledgeable choices about their weight-reduction plan and train in actual time.
We invested in Signos as a result of we imagine their huge dataset of nondiabetic glucose information can supply medical wellness options that each deal with the wants of right now, and might help unlock future options for a broader section of the inhabitants. Signos boasts a outstanding group, led by co-founder and CEO Sharam Fouladgar-Mercer. Sharam’s journey to deal with weight administration stems from private expertise, and his skilled background in information science and enterprise capital makes him well-suited to steer this endeavor. Co-founder Will Dixon’s medical experience, having labored in numerous medical roles, and CMO Hannah Russin’s development and advertising acumen from her time at Lyft and Embark Veterinary, additional strengthen Signos’ management and potential.
Our funding in Signos underscores the necessity for an efficient weight administration resolution that counters right now’s limitations of excessive prices, unintended effects, and poor long-term efficacy. We’re excited to again Signos and imagine the corporate’s real-time, data-driven monitoring capabilities will propel it to turn out to be the most effective at school non-medication weight reduction resolution available in the market.
Caroline O’Connor is an investor at Samsung Subsequent. Fellow investor Rameen Rana supported this funding. Samsung Subsequent’s funding technique is restricted to its personal views and doesn’t mirror the imaginative and prescient or technique of every other Samsung enterprise unit, together with, however not restricted to, Samsung Electronics.
